Program
ebselen
Also written as “Ebselen”, “SPI-1005” and “SPI-1005 Ebselen 200mg Capsule x1”.
Its studies are mostly in Meniere Disease · Hearing Loss · COVID-19 · Ototoxicity · Hearing Loss, Noise-Induced, led by Sound Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sound Pharmaceuticals | 123 open or running | phase 3since Jun 8, 2020 | Sep 29, 2011 | Dec 2026phase 3 · NCT06859788 |
Also a collaborator on its studies: MED-EL Elektromedizinische Geräte GesmbH.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 29, 2011First study: phase 2 study in Hearing LossFirst studyNCT01444846 · 83 enrolled · United States
- Oct 7, 2011Phase 2 study in Lung NeoplasmsNCT01451853 · United States
- Oct 10, 2011Phase 1 study in Hearing LossNCT01452607 · 32 enrolled · United States
- Nov 2, 2015Phase 2 study in Meniere DiseaseNCT02603081 · 40 enrolled · United States
- May 18, 2016Phase 2 study in Hearing Loss, Noise-InducedNCT02779192 · United States
- Jun 16, 2016Phase 2 study in OtotoxicityNCT02819856 · 35 enrolled · United States
- Oct 4, 2017Phase 2 study in Meniere DiseaseNCT03325790 · 149 enrolled · United States
- Jun 8, 2020Phase 3 study in Meniere DiseaseNCT04677972 · 220 enrolled · United States
- Jul 13, 20202 phase 2 studies in COVID-19NCT04484025, NCT04483973
- Mar 25, 2024Phase 2 study in Hearing LossNCT06340633 · 40 planned · United States
- Feb 28, 2025Phase 3 study in Meniere DiseaseNCT06859788 · 200 enrolled · United States
Ahead
- Dec 2026Primary completion: phase 3 study in Meniere DiseaseNCT06859788
- Dec 2026Primary completion: phase 2 study in Hearing LossNCT06340633
TargetBeta
“Therefore, the investigators now have substantial data that indicates that ebselen is a valid means of testing IMPase inhibition as a potential antidepressant mechanism in a clinical population of TRD patients, using an experimental medicine approach.”study text, by rule · the study
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06859788Meniere Disease · United States | 3 | Active, not recruiting | Dec 2026 | 200 |
| NCT06340633Hearing Loss · United States | 2 | Recruiting | Dec 2026 | 40 |
| NCT04484025COVID-19 · United States | 2 | By invitation | Dec 31, 2023 | 60 |
| NCT04483973COVID-19 · United States | 2 | Completed | May 5, 2023 | 25 |
| NCT04677972Meniere Disease · United States | 3 | Completed | Sep 19, 2023 | 220 |
| NCT03325790Meniere Disease · United States | 2 | Completed | Apr 30, 2019 | 149 |
| NCT02819856Ototoxicity · United States | 2 | Completed | Apr 7, 2023 | 35 |
| NCT02779192Hearing Loss, Noise-Induced · United States | 2 | Withdrawn | Jun 2026 | 0 |
| NCT02603081Meniere Disease · United States | 2 | Completed | Aug 2017 | 40 |
| NCT01452607Hearing Loss · United States | 1 | Completed | Aug 2006 | 32 |
| NCT01451853Lung Neoplasms · United States | 2 | Withdrawn | Jun 2026 | 0 |
| NCT01444846Hearing Loss · United States | 2 | Completed | Dec 2013 | 83 |
How it is read
Names in the registry
- “Ebselen”, 5 entries
- “SPI-1005”, 2 entries
- “SPI-1005 Ebselen 200mg Capsule x1”, 1 entry
- “SPI-1005 Ebselen 200mg Capsule x2”, 1 entry
- “SPI-1005 Ebselen 200mg Capsule x3”, 1 entry
Conditions, from the studies’ own filings
- Meniere Disease, 4 studies
- Hearing Loss, 3 studies
- COVID-19, 2 studies
- Ototoxicity, 1 study
- Hearing Loss, Noise-Induced, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.